BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19765885)

  • 1. In the human urothelium and suburothelium, intradetrusor botulinum neurotoxin type A does not induce apoptosis: preliminary results.
    Kessler TM; Khan S; Panicker JN; Elneil S; Brandner S; Fowler CJ; Roosen A
    Eur Urol; 2010 May; 57(5):879-83. PubMed ID: 19765885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
    Haferkamp A
    Eur Urol; 2008 Jun; 53(6):1253. PubMed ID: 18343561
    [No Abstract]   [Full Text] [Related]  

  • 3. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
    Apostolidis A; Jacques TS; Freeman A; Kalsi V; Popat R; Gonzales G; Datta SN; Ghazi-Noori S; Elneil S; Dasgupta P; Fowler CJ
    Eur Urol; 2008 Jun; 53(6):1245-53. PubMed ID: 18343564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete continence after botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks.
    Khan S; Panicker J; Roosen A; Gonzales G; Elneil S; Dasgupta P; Fowler CJ; Kessler TM
    Eur Urol; 2010 May; 57(5):891-6. PubMed ID: 19394133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration.
    Datta SN; Roosen A; Pullen A; Popat R; Rosenbaum TP; Elneil S; Dasgupta P; Fowler CJ; Apostolidis A
    J Urol; 2010 Dec; 184(6):2578-85. PubMed ID: 21030043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.
    Abdel-Meguid TA
    J Urol; 2010 Dec; 184(6):2423-8. PubMed ID: 20952003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment.
    Roosen A; Datta SN; Chowdhury RA; Patel PM; Kalsi V; Elneil S; Dasgupta P; Kessler TM; Khan S; Panicker J; Fry CH; Brandner S; Fowler CJ; Apostolidis A
    Eur Urol; 2009 Jun; 55(6):1440-8. PubMed ID: 19054608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial comment on: complete continence after botulinum neurotoxin type a injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks.
    Giannantoni A
    Eur Urol; 2010 May; 57(5):896. PubMed ID: 19394135
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment on: complete continence after botulinum neurotoxin type a injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks.
    Kilinc M; Guven S
    Eur Urol; 2010 May; 57(5):895-6. PubMed ID: 19394134
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
    Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
    J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection.
    Khan S; Kessler TM; Apostolidis A; Kalsi V; Panicker J; Roosen A; Gonzales G; Haslam C; Elneil S; Fowler CJ; Dasgupta P
    J Urol; 2009 Apr; 181(4):1773-8. PubMed ID: 19233414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical electromotive botulinum toxin type A administration--part II: Clinical application.
    Kajbafzadeh AM; Ahmadi H; Montaser-Kouhsari L; Sharifi-Rad L; Nejat F; Bazargan-Hejazi S
    Urology; 2011 Feb; 77(2):439-45. PubMed ID: 20800886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis.
    Khan S; Game X; Kalsi V; Gonzales G; Panicker J; Elneil S; Apostolidis A; Hamid R; Dasgupta P; Kessler TM; Fowler CJ
    J Urol; 2011 Apr; 185(4):1344-9. PubMed ID: 21334639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Mouttalib S; Khan S; Castel-Lacanal E; Guillotreau J; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    BJU Int; 2010 Dec; 106(11):1677-80. PubMed ID: 20590550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Input from a specialized nurse consultation in the management of detrusor overactivity treated with intradetrusor injections of botulinum toxin in urology department. Pilot study].
    Le Gal S; Safsaf A; Galliot I; Catovic B; Grise P
    Prog Urol; 2010 Sep; 20(8):584-9. PubMed ID: 20832036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.
    Kuo HC; Liao CH; Chung SD
    Eur Urol; 2010 Dec; 58(6):919-26. PubMed ID: 20864251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].
    Bentaleb Y; Castel-Lacanal E; Sallusto F; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    Prog Urol; 2008 Jul; 18(7):449-55. PubMed ID: 18602606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Seniority of neurobladder and effectiveness of a first intradetrusor injection of botulinum toxin].
    Lacout M; Guinet-Lacoste A; Popoff M; Verollet D; Lebreton F; Amarenco G
    Prog Urol; 2015 Sep; 25(11):642-8. PubMed ID: 26094097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study evaluating the safety of intradetrusor injections of botulinum toxin type A: investigation of generalized spread using single-fiber EMG.
    Schnitzler A; Genet F; Durand MC; Roche N; Bensmail D; Chartier-Kastler E; Denys P
    Neurourol Urodyn; 2011 Nov; 30(8):1533-7. PubMed ID: 21661038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity.
    Reitz A; Denys P; Fermanian C; Schurch B; Comperat E; Chartier-Kastler E
    Eur Urol; 2007 Dec; 52(6):1729-35. PubMed ID: 17884281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.